🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A reporter gets cancer -- and learns the story of how Revlimid, one of the most expensive cancer drugs, became so expensive. By David Armstrong. Everyone I know in the biotech industry has heard the basic outlines of this story, but seeing David tell it in such personal detail

🧵Key takeaways from White House officials on Most Favored Nations (MFN) Executive Order: The who and how: 1) USTR and Commerce Dept legal action against other countries to protect US co's from "discriminatory" practices that keep costs lower

Anyone know what this part of the "most-favored nation" drug pricing EO means for U.S. FDA given the language "maybe be unsafe, ineffective, or improperly marketed"? At worst, FDA could withdraw drugs that are thought to be, but not necessarily proven to be ineffective or unsafe?

Must-read report from Bernie Sanders ahead of tomm's HELP Committee Dems Senate HELP Committee GOP hearing w/HHS Secretary RFK Jr. detailing the many ways he & the President are destroying biomedical research, worsening healthcare access, & harming patients through misinformation: help.senate.gov/dem/newsroom/p…

CBO projects a reduction in Medicaid coverage of 10.3 million from the Republican bill, with much of that likely coming from work and reporting requirements. Yet, it expects employer-sponsored health coverage to increase by just 800,000.

We summarized the draft Medicaid provisions in the reconciliation bill ahead of the Energy and Commerce Committee mark-up. We’ll track changes and updates to health provisions as the bill evolves. Get the details and keep track: on.kff.org/3FfHWiZ

So proud of our CRRIT Yale School of Medicine students & NCSP at Yale fellows for presenting their research projects on the evidence underlying U.S. FDA approvals, FDA safety actions, costs of care, drug pricing, & more at #SGIM25! SGIM Joseph Ross Reshma Ramachandran

For New York Times Opinion I joined a dozen colleagues to offer concrete ways to save health and science at a time of immense change and uncertainty. With timely and important perspectives from Reshma Ramachandran, Maia Szalavitz, Dr. Josh Green, and many others. nytimes.com/2025/05/19/opi…

Come work with me at NYU Law! NYU is hiring a clinical teaching fellow to support the Science, Health & Information Clinic (which is moving with me to NYU) and NYU's long-running Technology Law & Policy Clinic (where I was the fellow 2019-21)! DM or email with Qs! [email protected]

Honored to present our work #ASCO25! Grateful to my mentors Reshma Ramachandran, Aaron Mitchell, and Yale CRRIT team for incredible guidance, Conquer Cancer, the ASCO Foundation for recognizing our research, and Yale IM Traditional Residency Program family for supporting me to attend this conference during an inpatient rotation!

Beautiful evening celebrating Dr. Reshma Ramachandran, recipient of The Bernard Lown Award for Social Responsibility for her work promoting equitable access to medicines, mobilizing physicians nationwide to challenge pharmaceutical industry influence, and advancing legislative reforms

Truly honored to receive the Bernard Lown Award for Social Responsibility from the Lown Institute. Dr. Lown's persistence & ability to mobilize the public against injustice are lessons I will carry forward as we continue to fight for a health system centered around our patients.